Company news: Pfizer, fish oil

Share this article:
A study published in The Journal of the American Medical Association said taking omega 3 fish oil supplements doesn't lower a patient's risk of cardiac death, sudden death, heart attack or stroke. The authors came to their conclusions after analyzing previous studies that encompassed almost 70,000 patients. The article noted that patients and healthcare providers are stuck navigating guidelines that contains shades of meaning that don't quite overlap, but don't exactly contradict each other, including medical society recommendations to take fish oil supplements if patients have had heart attacks, compared to the FDA's approval for fish oil supplements to help lower triglyceride levels. Wednesday's study complements an April 9 study that was published in Archives of Internal Medicine that said there wasn't enough evidence to support fish oil as a way to ward off heart disease.

The World Health Organization gave the OK to give adults age 50 and older Pfizer's pneumococcal vaccine, Prevnar 13, also known by the alternate spelling Prevenar 13. The NGO greenlighted the vaccine for infants and children up to age five just two years ago to help protect them from invasive pneumococcal disease, pneumonia and otitis media. Pfizer said in a statement that it is ramping up production to help meet the anticipated uptick in demand.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.